REMARKS / ARGUMENTS

In response to the restriction requirement under 35 USC 121 and 372, Applicant elects the claims of Group I. However, Applicants request reconsideration of the restriction requirement because the causes of the hypecalcemia, parathyroid adenoma, parathyroid hyperplasia and parathyroid carcinoma, are all forms of hyperparathyroidism. See claim 8 and the specification at page 3, last two paragraphs.

Entry of this response is requested and an action on the merits is awaited.

Respectfully submitted,

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080 (862) 778-7824

Date: July 16, 2009

George R. Dohmann Attorney for Applicant Reg. No. 33,593